Pennine Acute screens first UK participant to a diabetes study

Date: 07 April 2015

Time: 01:00

We would like to congratulate researchers at The Pennine Acute Hospitals NHS Trust who have screened the first participant in the UK to a diabetes trial.

The phase 2a study’s purpose is to find out if a new investigational medication, when given together with pregabalin (Lyrica®) or gabapentin, is effective and safe in reducing pain intensity in patients suffering from neuropathic pain of diabetic origin. Pregabalin and gabapentin are approved prescription medicines that are used to treat neuropathic pain.

The new investigational product is a type of drug known as a DENKI inhibitor and works by enhancing the body’s natural pain control mechanism. The drug hasn’t been approved for the treatment of neuropathic pain of diabetic origin and is considered experimental.

Prof Bhatnagar is the study’s Principal Investigator and he’s supported by three research nurses: Joanne Shaw, Judy Muir and Louise Morby.

The Trust was able to screen a potential participant speedily due to their collaborative approach to working across their various hospital sites. Participants can be recruited from any of the Trust’s four hospitals as sub-investigators are based within each.

The first participant was found by one of the research nurses at North Manchester General Hospital, but seen at Royal Oldham Hospital as this was most convenient for the research team and the patient.

  • Summary:
    The CRN: Greater Manchester-based Trust is testing a new medication to reduce neuropathic pain of diabetic origin.
  • Include on homepage (one at a time):
  • Areas of the site this news is applicable to:
  • LCRN:
  • Year of publication:
  • Specialty:
  • News filter:

You may also be interested in